THE HEART AND SOUL OF TEXRAY
Texray has developed the first radiation protection textile in the world, to address the need for improved radiation protection for medical practitioners. The patented technology platform is currently used in novel products, designed to reduce scatter radiation during fluoroscopy-guided interventions.
CLINICAL EVALUATION
CLINICAL EVALUATION
Prof S. Rohde and Dr F. Bärenfänger, Dortmund Germany, recently performed a scientific assessment of Texray novel head protectors concluding dose reduction up to 97%.
PHANTOM STUDY
PHANTOM STUDY
There is no cut-off point for radiation-induced DNA damage. Texray patented innovations reduce scatter with an additional 74% compared to when wearing a traditional thyroid collar.
LOCAL DISTRIBUTORS
LOCAL DISTRIBUTORS
We distribute to most countries directly, contact us if there is no distributor currently listed in your country.
Texray scientific poster published during the largest interventional cardiovascular course in Europe
Swedish innovation reduces radiation doses for interventional operators Gothenburg, Sweden | June 10, 2022 | Texray, the Swedish innovation company developing Occupational Radiation Equipment, today announces the acceptance for a...
Fri, Jun 10, 22
Texray available in Spain
Announcement | Texray AB Gothenburg, Sweden | May 31st, 2022 | Medcor distributes Texray radiation protection equipment in Spain Texray is pleased to announce a new nationwide distribution agreement for Spain with Medcor. ...
Tue, May 31, 22
Texray available in Canada
Announcement | Texray AB Gothenburg, Sweden | March 28h, 2022 | RSK Medical to distribute Texray Radiation Protection Equipment in Canada. Texray is pleased to announce a new nationwide distribution agreement for Canada...
Thu, Apr 28, 22
Texray Faculty members at key medical meeting in London
Co-founding duo Petra Apell and Fredrik Gellerstedt have been invited to join as Faculty members to the 44th International Charing Cross (CX) Vascular and Endovascular Symposium Challenges Update, London, UK....
Thu, Apr 07, 22